LabGenomics develops Corona 19 diagnostic kit for fast inspection, eyes entry in U.S., world market
상태바
LabGenomics develops Corona 19 diagnostic kit for fast inspection, eyes entry in U.S., world market
  • Thomasmore Kim 기자
  • 승인 2020.03.20 11:13
  • 댓글 0
이 기사를 공유합니다

Discloses CEO SungHyun Chin of LabGenomics in Seoul

Korea, and the entire world, for that matter, is in an emergency situation with the fast spread of the corona woes worldwide. At this juncture, CEO SungHyun Chin of LabGenomics Co., Ltd, disclosed that his company has developed the world's best diagnostic kit and disclosed that he has urgently requested cooperation with the Food and Drug Administration of the United States.

Founded in 2010, LabGenomics is a leading company in Korea, who pioneered and entered the diagnosis and molecular diagnosis market through genetic analysis, CEO Chin is currently working with more than 200 hospitals through 20 centers.

'Labgun COVID-19' kit developed by LabGenomics
'Labgun COVID-19' kit developed by LabGenomics

Corona 19 diagnostic kit 'Labgun COVID-19' developed by LabGenomics applies real-time polymerase chain reaction (RT-PCR) to the technology, reads infection within 2 to 6 hours, and has 99% accuracy-according to CEO Chin.

CEO Chin said, “Corona 19 responding to a number of urgent responses in the midst of confusion in the world, LabGenomics has completed the registration of a corona 19 diagnostic kit as a supplier to the United Nations procurement organization.

The level of the supplier registered with the UN Procurement Agency is Level 1, and if the company develops a diagnostic product registered with the UN Procurement Agency, which is an international organization such as the World Health Organization (WHO), UNHCR (UNHCR) and the International Labor Organization (ILO).

In a press release on March 17, CEO Chin stated: “We are currently preparing for consultation with the CDC (US Center for Disease Control and Prevention) after requesting and requesting emergency use approval from the US FDA.” Chin said, “After we secure approval from the U.S. FDA for use, we plan to enter the US market through three state partners, namely in Nevada, Washington and New Jersey.”

CEO SungHyun Chin of the LabGenomics Co., Ltd.
CEO SungHyun Chin of the LabGenomics Co., Ltd.

Chin said: “In this urgent situation worldwide, Future Value Lab Co., Ltd., which operates a specialized overseas response team to supply overseas countries that need urgently the diagnostic kit Corona 19 from LabGenomics, is currently in the United States, the Middle East, Europe, and in total of over 30 countries in Southeast Asia where progress is being made with local partners in Consultations for rapid supply to large hospitals and health departments in some 30 countries of the world, including Canada, Australia, Japan, Indonesia, Malaysia, Kuwait, Spain, France, Israel, and Vietnam.”

“As countries around the world suffering from Corona 19 rapidly introduce success cases in Korea, including the world's best diagnostic technology, we hope that the confusion caused by Corona 19 around the world will quickly subside,” said CEO Chin.

 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.
주요기사